{"title":"Exosomes as therapy for cancer","authors":"Rocío Retamales-Ortega, M. L. Oróstica","doi":"10.15761/icst.1000357","DOIUrl":"https://doi.org/10.15761/icst.1000357","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 66-year-old male patient with was admitted to hospital with complaints of fatigue and shortness of breath. In the chest X-ray of the patient, homogeneous density increase was observed in the lower zone of the right lung, suggesting pleural effusion and showing Damoiseau's line. In the patient who underwent thoracentesis, pleural fluid in the form of yellow pus and empyema was seen. The pleural fluid biochemistry was in the character of exudate. Thoracic computed tomography (CT) was performed in the patient who underwent closed underwater drainage with tube thoracostomy. Pleural effusion was reaching 8 cm. in the right hemithorax. The size of the spleen was increased, the liver parenchyma was heterogeneous. In the follow-ups, although the pleural effusion and Damoiseau line of the patient were erased, the fluid continued to come out of the drain as a daily empyema; the patient's clinical and laboratory tests were not compatible with empyema. In addition, a possible hematological malignancy was considered due to low Hb, leukocyte, platelet levels, and hepatosplenomegaly. Chylothorax was taken into the differential diagnosis and triglyceride and cholesterol were sent from the pleural fluid. Triglyceride was high in pleural fluid. No malignant cells were seen in pleural fluid cytology. Positron emission tomography (PET)/CT was performed to determine the etiology in the patient who was diagnosed with chylothorax. There were dense hypermetabolic lymphadenopathy masses starting from the level of the 8th thoracic vertebra up to the retrocrural area in the prevertebral area. Spleen sizes were increased and there were intense hypermetabolic involvements. Involvement due to lymphoproliferative diseases was considered in the foreground. Mediastinoscopy was performed. Biopsies were taken from mass in the paraesophageal area (posterior mediastinum). The pathology result of the biopsies was "Diffuse Large B-Cell Lymphoma". The patient was referred to hematology and oncology clinics for treatment and discharged.
{"title":"A case of chylothorax due to diffuse large B-Cell lymphoma","authors":"F. Şahin","doi":"10.15761/icst.1000360","DOIUrl":"https://doi.org/10.15761/icst.1000360","url":null,"abstract":"A 66-year-old male patient with was admitted to hospital with complaints of fatigue and shortness of breath. In the chest X-ray of the patient, homogeneous density increase was observed in the lower zone of the right lung, suggesting pleural effusion and showing Damoiseau's line. In the patient who underwent thoracentesis, pleural fluid in the form of yellow pus and empyema was seen. The pleural fluid biochemistry was in the character of exudate. Thoracic computed tomography (CT) was performed in the patient who underwent closed underwater drainage with tube thoracostomy. Pleural effusion was reaching 8 cm. in the right hemithorax. The size of the spleen was increased, the liver parenchyma was heterogeneous. In the follow-ups, although the pleural effusion and Damoiseau line of the patient were erased, the fluid continued to come out of the drain as a daily empyema; the patient's clinical and laboratory tests were not compatible with empyema. In addition, a possible hematological malignancy was considered due to low Hb, leukocyte, platelet levels, and hepatosplenomegaly. Chylothorax was taken into the differential diagnosis and triglyceride and cholesterol were sent from the pleural fluid. Triglyceride was high in pleural fluid. No malignant cells were seen in pleural fluid cytology. Positron emission tomography (PET)/CT was performed to determine the etiology in the patient who was diagnosed with chylothorax. There were dense hypermetabolic lymphadenopathy masses starting from the level of the 8th thoracic vertebra up to the retrocrural area in the prevertebral area. Spleen sizes were increased and there were intense hypermetabolic involvements. Involvement due to lymphoproliferative diseases was considered in the foreground. Mediastinoscopy was performed. Biopsies were taken from mass in the paraesophageal area (posterior mediastinum). The pathology result of the biopsies was \"Diffuse Large B-Cell Lymphoma\". The patient was referred to hematology and oncology clinics for treatment and discharged.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Scarinci Andrea, De Peppo Valerio, Grazi Gian Luca
{"title":"A case report of giant hepatic hemangioma spontaneous regression in adult, non-cirrhotic patient and literature review","authors":"Scarinci Andrea, De Peppo Valerio, Grazi Gian Luca","doi":"10.15761/icst.1000361","DOIUrl":"https://doi.org/10.15761/icst.1000361","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67479040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign neoplasm, predominantly occurring in middle-aged women. When first reported, PSP was thought to be vascular in origin and named pulmonary sclerosing hemangioma because of its high morphological similarity to cutaneous sclerosing hemangioma. Thanks to electron microscopy and immunofluorescence, it has been defined as being primitive respiratory epithelium-oriented and renamed as PSP [1].
{"title":"Sclerosing Pneumocytoma: A Carcinoma Mimicker","authors":"Li-cheng Song, Peng Yan, G. Mo","doi":"10.15761/icst.1000352","DOIUrl":"https://doi.org/10.15761/icst.1000352","url":null,"abstract":"Pulmonary sclerosing pneumocytoma (PSP) is a rare benign neoplasm, predominantly occurring in middle-aged women. When first reported, PSP was thought to be vascular in origin and named pulmonary sclerosing hemangioma because of its high morphological similarity to cutaneous sclerosing hemangioma. Thanks to electron microscopy and immunofluorescence, it has been defined as being primitive respiratory epithelium-oriented and renamed as PSP [1].","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evinacumab - a new drug in the treatment of homozygous familial hypercholesterolaemia","authors":"S. Surma, Monika Romańczyk, K. Filipiak","doi":"10.15761/icst.1000355","DOIUrl":"https://doi.org/10.15761/icst.1000355","url":null,"abstract":"","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Collard, N. Guedj, Julien Tourneur-Marsille, M. Albuquerque, L. Maggiori, P. Hammel, X. Tréton, Y. Panis, E. Ogier-Denis
Introduction: Immunity of colitis-associated colorectal cancer (CAC) differs fundamentally from that of the sporadic form. The aim of this study was to evaluate whether this difference could potentiate the efficacy of immune-checkpoint inhibitor anti-PD1 against CAC. Methods: CAC tumorigenesis was induced by azoxymethane (AOM) followed by three cycles of dextran sodium sulfate (DSS) in mice. Two weeks after the end of DSS, mice were treated with anti-PD1 antibody (n=9) or with isotype antibody (n=9). The severity of clinical and histological colitis, tumor counts, and infiltration of CD8+ T-lymphocytes and neutrophils were compared. Results: The anti-PD1 antibody did not aggravate the colitis as exemplified by the absence of differences in weight loss (p=0.424) and in the standardized pathological scores (p=1.000) compared to those of the control. On macroscopic examination, the median number of tumors was 24.0 [21.5/31.0] in treated mice and 17.0 [4.0/23.5] in controls (p=0.037). The percentage of tumor tissue within the entire colonic epithelium was significantly higher in treated mice (33.1% [27.2/39.0]) than in controls (15.3% [8.1/25.0]) (p=0.003). The intra-tumoral CD8+ T-lymphocyte density was similar between the two groups (p=0.546). In contrast, CD8+ T-lymphocyte density was significantly higher in non-tumor colonic epithelium in treated mice than in controls (p=0.019). Regarding innate immunity, neutrophil density was similar within the tumors (p=0.864) and augmented in non-tumor colonic epithelium in treated mice compared with controls (p=0.012). Conclusion: Unexpectedly, checkpoint inhibitor anti-PD1 treatment of CAC stimulates tumor proliferation without flaring-up the colitis. *Correspondence to: Eric Ogier-Denis, Laboratory of intestinal inflammation, center of research on inflammation, UMR1149, INSERM, University of Paris, 16 rue Henri Huchard, 75018, France, Tel: +33157277307, Fax: +3315727746, E-mail: eric.ogier-denis@inserm.fr
结肠炎相关结直肠癌(CAC)的免疫与散发性结直肠癌的免疫有本质的不同。本研究的目的是评估这种差异是否可以增强抗pd1免疫检查点抑制剂对CAC的疗效。方法:采用氮氧甲烷(AOM)和葡聚糖硫酸钠(DSS)三次循环诱导小鼠CAC发生。DSS结束2周后，分别给予抗pd1抗体(n=9)或同型抗体(n=9)。比较临床和组织学结肠炎的严重程度、肿瘤计数、CD8+ t淋巴细胞和中性粒细胞的浸润情况。结果:与对照组相比，抗pd1抗体没有加重结肠炎，在体重减轻(p=0.424)和标准化病理评分(p=1.000)方面没有差异。肉眼检查，实验组小鼠肿瘤中位数为24.0[21.5/31.0]，对照组为17.0 [4.0/23.5](p=0.037)。治疗组肿瘤组织在整个结肠上皮内的比例(33.1%[27.2/39.0])显著高于对照组(15.3% [8.1/25.0])(p=0.003)。两组肿瘤内CD8+ t淋巴细胞密度差异无统计学意义(p=0.546)。相比之下，治疗小鼠非肿瘤结肠上皮CD8+ t淋巴细胞密度显著高于对照组(p=0.019)。在先天免疫方面，与对照组相比，治疗小鼠肿瘤内中性粒细胞密度相似(p=0.864)，非肿瘤结肠上皮中性粒细胞密度增加(p=0.012)。结论:出乎意料的是，检查点抑制剂抗pd1治疗CAC刺激肿瘤增殖而不爆发结肠炎。*通讯:Eric Ogier-Denis，肠道炎症实验室，炎症研究中心，UMR1149，巴黎大学INSERM, Henri Huchard街16号，法国，75018，电话:+33157277307，传真:+3315727746,E-mail: eric.ogier-denis@inserm.fr
{"title":"Immune-checkpoint inhibitor anti-PD1 aggravates colitis-associated colorectal cancer without enhancing intestinal inflammation","authors":"M. Collard, N. Guedj, Julien Tourneur-Marsille, M. Albuquerque, L. Maggiori, P. Hammel, X. Tréton, Y. Panis, E. Ogier-Denis","doi":"10.15761/icst.1000334","DOIUrl":"https://doi.org/10.15761/icst.1000334","url":null,"abstract":"Introduction: Immunity of colitis-associated colorectal cancer (CAC) differs fundamentally from that of the sporadic form. The aim of this study was to evaluate whether this difference could potentiate the efficacy of immune-checkpoint inhibitor anti-PD1 against CAC. Methods: CAC tumorigenesis was induced by azoxymethane (AOM) followed by three cycles of dextran sodium sulfate (DSS) in mice. Two weeks after the end of DSS, mice were treated with anti-PD1 antibody (n=9) or with isotype antibody (n=9). The severity of clinical and histological colitis, tumor counts, and infiltration of CD8+ T-lymphocytes and neutrophils were compared. Results: The anti-PD1 antibody did not aggravate the colitis as exemplified by the absence of differences in weight loss (p=0.424) and in the standardized pathological scores (p=1.000) compared to those of the control. On macroscopic examination, the median number of tumors was 24.0 [21.5/31.0] in treated mice and 17.0 [4.0/23.5] in controls (p=0.037). The percentage of tumor tissue within the entire colonic epithelium was significantly higher in treated mice (33.1% [27.2/39.0]) than in controls (15.3% [8.1/25.0]) (p=0.003). The intra-tumoral CD8+ T-lymphocyte density was similar between the two groups (p=0.546). In contrast, CD8+ T-lymphocyte density was significantly higher in non-tumor colonic epithelium in treated mice than in controls (p=0.019). Regarding innate immunity, neutrophil density was similar within the tumors (p=0.864) and augmented in non-tumor colonic epithelium in treated mice compared with controls (p=0.012). Conclusion: Unexpectedly, checkpoint inhibitor anti-PD1 treatment of CAC stimulates tumor proliferation without flaring-up the colitis. *Correspondence to: Eric Ogier-Denis, Laboratory of intestinal inflammation, center of research on inflammation, UMR1149, INSERM, University of Paris, 16 rue Henri Huchard, 75018, France, Tel: +33157277307, Fax: +3315727746, E-mail: eric.ogier-denis@inserm.fr","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Geetanjali Singh, K. Bendale, S. Talwelkar, Shital Pawade, P. Gera, A. Patil, P. Chavan, Sureshkannan K Subramanian, P. Chaudhari
Background & Aims: Hepatocellular carcinoma (HCC) is a global challenge due to rising incidence and high mortality rate among the affected individuals. Establishing successful animal models of HCC is, therefore, crucial for basic and translational studies of HCC. Present study was undertaken to develop orthotopic syngeneic rat HCC model to study new diagnostic and therapeutic strategies for human HCC research. Methods : Rat Novikoff hepatoma cells were injected beneath the capsule of left lobe of liver in fifty-five sprague dawley rats. Study was divided in three phases, 15 Animals in phase-I were injected with 4x10 6 cells in 100µl DMEM, 15 animals in phase-II with 2x10 6 cells in 50µl and 30 animals in phase-III with 3 x10 6 cells in a 100µl DMEM. Tumor induction rate, tumor size and progression and mortality rate was evaluated and assessed using serial µPET-CT imaging till four weeks. F-18 Flurodeoxyglucose was used as metabolic imaging radiotracer and imaging findings were correlated grossly and histologically. Results : Phase-I animals showed 100% tumor induction rate but multiple intrahepatic and intra peritoneal masses with 100% mortality observed. Phase-II animals did not show any tumor. Phase-III animals showed 100% induction rate with controlled and diffused progression of hepatic tumor. CT images and sequential higher flurodeoxyglucose uptake in liver confirmed the progression of tumor. Gross examination and histology confirmed the presence of HCC. Conclusions: N1S1 cell induced orthotopic syngeneic HCC rat model with progressive controlled tumor growth and least mortality rate can be used to study new diagnostic techniques and plan new therapeutic strategies against HCC.
{"title":"Establishment of an orthotopic syngeneic rat model of hepatocellular carcinoma and its validation with microPET-CT imaging","authors":"Geetanjali Singh, K. Bendale, S. Talwelkar, Shital Pawade, P. Gera, A. Patil, P. Chavan, Sureshkannan K Subramanian, P. Chaudhari","doi":"10.15761/ICST.1000348","DOIUrl":"https://doi.org/10.15761/ICST.1000348","url":null,"abstract":"Background & Aims: Hepatocellular carcinoma (HCC) is a global challenge due to rising incidence and high mortality rate among the affected individuals. Establishing successful animal models of HCC is, therefore, crucial for basic and translational studies of HCC. Present study was undertaken to develop orthotopic syngeneic rat HCC model to study new diagnostic and therapeutic strategies for human HCC research. Methods : Rat Novikoff hepatoma cells were injected beneath the capsule of left lobe of liver in fifty-five sprague dawley rats. Study was divided in three phases, 15 Animals in phase-I were injected with 4x10 6 cells in 100µl DMEM, 15 animals in phase-II with 2x10 6 cells in 50µl and 30 animals in phase-III with 3 x10 6 cells in a 100µl DMEM. Tumor induction rate, tumor size and progression and mortality rate was evaluated and assessed using serial µPET-CT imaging till four weeks. F-18 Flurodeoxyglucose was used as metabolic imaging radiotracer and imaging findings were correlated grossly and histologically. Results : Phase-I animals showed 100% tumor induction rate but multiple intrahepatic and intra peritoneal masses with 100% mortality observed. Phase-II animals did not show any tumor. Phase-III animals showed 100% induction rate with controlled and diffused progression of hepatic tumor. CT images and sequential higher flurodeoxyglucose uptake in liver confirmed the progression of tumor. Gross examination and histology confirmed the presence of HCC. Conclusions: N1S1 cell induced orthotopic syngeneic HCC rat model with progressive controlled tumor growth and least mortality rate can be used to study new diagnostic techniques and plan new therapeutic strategies against HCC.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Smetana, H. Klamová, D. Mikulenková, J. Schwarz
The computer assisted optical image densitometry indicated that myeloid leukemias were characterized by two subpopulations of progenitor cells classified according to the heterochromatin condensation state (HChCS). The first subpopulation of these cells was characterized by a larger HChCS in the nuclear central regions than in the nuclear periphery. Such progenitors seemed to possess the potential for further differentiation and were predominantly present in patients suffering from the chronic phase of chronic myelocytic and acute monoblastic leukemias. The second subpopulation of progenitors was characterized by a marked similarity of HChCS in both central and peripheral nuclear regions. That similarity was also noted in terminally differentiated granulocytes and monocytes. Thus, these progenitors were in the state of premature terminal differentiation and reflected the altered differentiation process. The large dominant incidence of such progenitors was noted in acute myeloblastic, acute promyelocytic and acute myelomonocytic leukemias with a known alteration of the further differentiation process.
{"title":"Two subpopulations of progenitors of leukemic lineages in human myeloid leukemias exhibit different heterochromatin condensation state in central and peripheral nuclear regions (A morphological note with additional original observations)","authors":"K. Smetana, H. Klamová, D. Mikulenková, J. Schwarz","doi":"10.15761/ICST.1000343","DOIUrl":"https://doi.org/10.15761/ICST.1000343","url":null,"abstract":"The computer assisted optical image densitometry indicated that myeloid leukemias were characterized by two subpopulations of progenitor cells classified according to the heterochromatin condensation state (HChCS). The first subpopulation of these cells was characterized by a larger HChCS in the nuclear central regions than in the nuclear periphery. Such progenitors seemed to possess the potential for further differentiation and were predominantly present in patients suffering from the chronic phase of chronic myelocytic and acute monoblastic leukemias. The second subpopulation of progenitors was characterized by a marked similarity of HChCS in both central and peripheral nuclear regions. That similarity was also noted in terminally differentiated granulocytes and monocytes. Thus, these progenitors were in the state of premature terminal differentiation and reflected the altered differentiation process. The large dominant incidence of such progenitors was noted in acute myeloblastic, acute promyelocytic and acute myelomonocytic leukemias with a known alteration of the further differentiation process.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fang-Yuan Zhang, Run-Ze Li, Jia-Xin Li, Xing-Xing Fan, C. Xie, Liang Liu, Xiaojun Yao, E. Leung
Secreted PLA2 (sPLA2) enzyme, which shows the unique cellular properties and distinct biological roles, is the lipolytic enzyme that acts on glycerophospholipids to induce the release of free fatty acids (FAs). Many researches have reported the human sPLA2s are expressed abnormally in various cancers. But it is still not clear about the specific isoforms function of sPLA2 in these cancers, and its function roles in various cancers. In this review, we will introduce the mechanism and pathway of sPLA2 in cancers as well as the relationship with lipid metabolism. Then we will further discuss the novel technologies which can be applied to explore the action of particular sPLA2 enzyme in lung cancer and the mechanisms of drugs such as small molecule inhibitors or traditional Chinese medicines, with the potential to treat diseases associated with inflammation and lipid metabolism.
{"title":"Phospholipase A2 as a novel therapeutic target in lung cancer","authors":"Fang-Yuan Zhang, Run-Ze Li, Jia-Xin Li, Xing-Xing Fan, C. Xie, Liang Liu, Xiaojun Yao, E. Leung","doi":"10.15761/ICST.1000349","DOIUrl":"https://doi.org/10.15761/ICST.1000349","url":null,"abstract":"Secreted PLA2 (sPLA2) enzyme, which shows the unique cellular properties and distinct biological roles, is the lipolytic enzyme that acts on glycerophospholipids to induce the release of free fatty acids (FAs). Many researches have reported the human sPLA2s are expressed abnormally in various cancers. But it is still not clear about the specific isoforms function of sPLA2 in these cancers, and its function roles in various cancers. In this review, we will introduce the mechanism and pathway of sPLA2 in cancers as well as the relationship with lipid metabolism. Then we will further discuss the novel technologies which can be applied to explore the action of particular sPLA2 enzyme in lung cancer and the mechanisms of drugs such as small molecule inhibitors or traditional Chinese medicines, with the potential to treat diseases associated with inflammation and lipid metabolism.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67478499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Seidl, P. Bischoff, A. Schaefer, M. Esser, V. Janzen, A. Kovács
Purpose: This study investigated the oncologic outcome following transarterial chemoembolization (TACE) with irinotecan loaded spheres in patients with liver metastases of adenocarcinomas of right-, respectively left-sided colorectal origin (RSCC, LSCRC). Materials and methods: 21 Patients (pts) with unresectable monoor bilobar colorectal liver metastases (CRLM), liver-only or liver-dominant metastatic spread, with less than 25% of the liver parenchyma involved and progression after second line systemic chemotherapy underwent lobar irinotecan TACE. Tolerability, safety and oncologic outcome were assessed in terms of intervention-associated side effects, respectively local tumour control (LTC), progression free survival (PFS) and overall survival (mOS). Results: 16 pts with left-sided and 5 with right-sided colonic primary with a mean volumetric tumour burden of 5.27 ± 6.26%, median 2.89% (range 0.23 – 24.1%) received in total 49 TACE, in average 2.33 interventions per patient. Treatment-related abdominal pain occurred in 4.08% on the day of intervention and could sufficiently be controlled with pain medication on demand. LTC (CR, PR or SD) in the liver was achieved in 20/21 (95.2%), 19/21 (90.4%) and 16/21 (76.2%) patients at 1, 3 and 6 months, respectively. PFS was 5.5 mo in LSCRC, respectively 3.75 mo in RSCC. mOS was 33 mo after the first TACE in LSCRC, respectively 17 mo in RSCC. Conclusion: TACE with irinotecan loaded spheres is a safe and well tolerated procedure in the treatment of CRLM. The promising results in terms of mOS especially in tumours of left-sided origin deserve further investigation in larger prospective trials. *Correspondence to: Attila Kovács, Department of Diagnostic and Interventional Radiology and Neuroradiology, MediClin Robert Janker Klinik, Villenstraße 8, 53129 Bonn, Germany, Tel: +49 228 5306 – 501, Fax +49 228 5306 – 502, E-mail: attila.kovacs@mediclin.de
{"title":"TACE in colorectal liver metastases – different outcomes in right-sided and left-sided primary tumour location","authors":"S. Seidl, P. Bischoff, A. Schaefer, M. Esser, V. Janzen, A. Kovács","doi":"10.15761/icst.1000328","DOIUrl":"https://doi.org/10.15761/icst.1000328","url":null,"abstract":"Purpose: This study investigated the oncologic outcome following transarterial chemoembolization (TACE) with irinotecan loaded spheres in patients with liver metastases of adenocarcinomas of right-, respectively left-sided colorectal origin (RSCC, LSCRC). Materials and methods: 21 Patients (pts) with unresectable monoor bilobar colorectal liver metastases (CRLM), liver-only or liver-dominant metastatic spread, with less than 25% of the liver parenchyma involved and progression after second line systemic chemotherapy underwent lobar irinotecan TACE. Tolerability, safety and oncologic outcome were assessed in terms of intervention-associated side effects, respectively local tumour control (LTC), progression free survival (PFS) and overall survival (mOS). Results: 16 pts with left-sided and 5 with right-sided colonic primary with a mean volumetric tumour burden of 5.27 ± 6.26%, median 2.89% (range 0.23 – 24.1%) received in total 49 TACE, in average 2.33 interventions per patient. Treatment-related abdominal pain occurred in 4.08% on the day of intervention and could sufficiently be controlled with pain medication on demand. LTC (CR, PR or SD) in the liver was achieved in 20/21 (95.2%), 19/21 (90.4%) and 16/21 (76.2%) patients at 1, 3 and 6 months, respectively. PFS was 5.5 mo in LSCRC, respectively 3.75 mo in RSCC. mOS was 33 mo after the first TACE in LSCRC, respectively 17 mo in RSCC. Conclusion: TACE with irinotecan loaded spheres is a safe and well tolerated procedure in the treatment of CRLM. The promising results in terms of mOS especially in tumours of left-sided origin deserve further investigation in larger prospective trials. *Correspondence to: Attila Kovács, Department of Diagnostic and Interventional Radiology and Neuroradiology, MediClin Robert Janker Klinik, Villenstraße 8, 53129 Bonn, Germany, Tel: +49 228 5306 – 501, Fax +49 228 5306 – 502, E-mail: attila.kovacs@mediclin.de","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67477419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：